Kornimate/medical-research-clean huggingface dataset:
financial navigation study among young adult blood cancer survivors

Conditions: Survivorship; Cancer; Financial Stress

Summary: young adult cancer survivors (18-39y) are at increased risk of financial distress. this study seeks to better understand the financial challenges experienced by these individuals via quantitative serial assessments, study-based financial navigator encounters and an end of study qualitative interview.

this fully remote, multi-site study will evaluate the role of financial navigators in relieving financial distress in young adults (18-39y) who have completed treatment for blood cancer at least three years ago. serial assessments at study entry, 3-months, and 6-months measure financial distress measured using the study's primary outcome measure the personal financial wellness scale™ (pfw) (see below), hypothesized effect modifiers (emotional distress, self-efficacy, cognitive functioning), as well as care seeking, household finances and insurance characteristics. randomization will occur following completion of baseline measures (see below for description of study arms). in addition to a formal evaluation of the intervention at 3- and 6-months, an optional interview will occur following the 6-month assessment/navigation intervention period to gain further insight from participants about the acceptability of the intervention. for ethical considerations related to the topic of study, all participants will be provided with the leukemia \& lymphoma society's information specialist hotline.

Eligibility criteria:
inclusion criteria: 1. previous diagnosis and treatment of blood cancer (leukemia, lymphoma, myeloma, myelodysplastic syndrome, or myeloproliferative neoplasm) 2. current age between 18-39 years old 3. blood cancer diagnosis during childhood (0-17 years of age) or young adulthood (18-36 years of age) 4. at least three years post blood cancer diagnosis 5. off treatment for blood cancer or on a long-term regimen with an oral anti-cancer medication with stable disease 6. off treatment for a second cancer (non-blood cancer) or on a stable long-term regimen, such as hormone therapy or hormone replacement therapy 7. primary residence in united states 8. able to understand and read the english language exclusion criteria: * on parent or guardian's insurance
the effect of ultrasound-guided botulinum toxin injections on pain, functionality, spasticity, and range of motion in patients with post-stroke upper extremity spasticity

Conditions: Cerebrovascular Disorders; Spasticity, Muscle; Botulinum Toxin

Summary: the patients between the ages of 35-80 who developed spasticity in the upper extremity after stroke will be included.. botulinum toxin(bt-a) injection will be applied to the study group(n=16) and placebo injection to the control group(n=15) in addition to conventional rehabilitation and stretching exercises. evaluations will be made before the treatment, in the 2nd week, and in 3rd month after the treatment. pain relief will be evaluated with the visual analog scale(vas) and spasticity assessment will be done with the modified ashworth scale(mas). the functionality will be evaluated with fugl meyer assessment scale(fmas) and box block test(bbt).


Eligibility criteria:
inclusion criteria: * hemiplegia due to a cerebrovascular accident at least 1 month ago * cognitively competent * have spasticity of 1 and above according to the modified ashworth scale * receive at least 3 cubes in the box block test exclusion criteria: * patients with upper extremity brachial plexus lesions, * shoulder subluxation, * arthritis and joint contracture, * neglect syndrome, * cerebellar and brain stem lesions * those who did not accept the study
diaphragmatic echography in covid-19 pneumonia

Conditions: Pneumonia, Viral; Covid19; Respiratory Failure

Summary: we hypothesized that diaphragm thickness is concerned in acute respiratory failure of covid19 patients and its ultrasound measure at the begining of hospitalisation is a good predictor of poor outcome. a prospective observational non intervention study is designed.

to answer our hypothesis we will perform diaphragm ultrasound in the first 24hr hospitalized covid19 patients. in the ultrasound exploration we will assess diaphragm movility and thickness. we will also assess other clinical, biochemistry and radiological variables. the main outcome we want to analyze is the destination on discharge: home, respiratory intermediate critical unit or exitus.

Eligibility criteria:
inclusion criteria: * covid19 pneumonia acute respiratory failure (pao2 \<60mmhg) exclusion criteria: * invasive or non invasive ventilation within first 24h neuromuscular disease diaphragmatic paralysis

Keywords: covid19 pneumonia diaphragm ultrasound
relaxation with virtual reality on fatigue and comfort in hemodialysis patients

Conditions: Chronic Kidney Diseases

Summary: based on the task of providing the comfort of the patient, which is an indispensable part of the nursing profession, which many nurse theorists emphasize, there has been no study in the literature on the determination of the effect of virtual relaxation, which can be effective on the fatigue and comfort levels of patients receiving hemodialysis treatment. therefore, the aim of this study is to examine the effect of virtual reality and relaxation on fatigue and comfort in hemodialysis patients.

the patient will be prepared for relaxation with virtual reality and will be given a comfortable sitting position. the patient will watch the relaxation practice with virtual reality once during the hemodialysis treatment. the application will be terminated with the expiration of the virtual reality relaxation video. fatigue and comfort score will be measured after the application.

Eligibility criteria:
inclusion criteria: * receiving hemodialysis treatment for the last 6 months * receiving four-hour hemodialysis treatment three times a week * 18 years or older * deaf and visually impaired * without cognitive and psychiatric diagnosis * open to communication and cooperation * patients who agreed to participate in the study exclusion criteria: * kidney transplant * discomfort due to virtual reality glasses * suspected/diagnosed covid-19 * patients who want to leave the study voluntarily * death
observational and prospective registry on cardiac contractility modulation (ccm) therapy

Conditions: Heart Failure, Systolic

Summary: observational and perspective study with acute and chronic endpoint.

this registry includes patients who have undergone implantation of the cardiac contractility modulation device due to the presence of heart failure with reduced left ventricular systolic function and symptomatic despite optimal therapy, as indicated in the guidelines of the esc of 2016 and the expert consensus document of the esc heart failure group published in may 2019 for to assess the benefits after the ccm device.

Eligibility criteria:
inclusion criteria: * male or non-pregnant female, aged 18 or older; * chronic heart failure with symptomatic left ventricular systolic function; (nyha class ii-iva) with or without device already implanted (for example aicd, pace-maker); * appropriate and optimized medical therapy * patient signed and dated informed consent form at enrollment; * life expectancy\> 1 year due to the absence of comorbidities that reduce the prognosis exclusion criteria: * absence of venous access available for implant; * contraindication to the interventional procedure of ccm device implant (for example presence of mechanical tricuspid vale); * pregnant patients

Keywords: heart failure quality of life cardiac contractility modulation
long-term effect of combined citrulline and nitrate-rich beetroot extract supplementation

Conditions: Citrulline; Nitrate; Athletes

Summary: citrulline (cit) and nitrate-rich beetroot extract (beet) are widely studied ergogenic aids. however, both supplements have been studied in sort-term and isolated. to the best of the authors' knowledge, the effects of combining both supplements on exercise-induced muscle damage (eimd) and hormone status have not been investigated to date. therefore, the main purpose of this study was to determine the effect and degree of potentiation of the long-term (9 weeks) mixture of 3 g/day of cit plus 2.1 g/day of beet (300 mg/day of nit) supplementation on eimd markers (urea, creatinine, ast, alt, ggt, ldh and ck) and anabolic/catabolic hormone status (testosterone, cortisol and testosterone cortisol ratio (t/c)) in male trained triathletes. this study was a double-blind, placebo-controlled trial where participants (n = 32) were randomized into 4 different groups: placebo group (plg; n = 8), cit group (citg; 3 g/day of cit; n = 8), beet group (beetg; 2.1 g/day of beet (300 mg/day of nit) ; n = 8) and cit-nit group (cit-beetg; 3 g/day of cit plus 2.1 g/day of beet (300 mg/day of nit); n = 8). blood samples were collected from all participants at baseline (t1) and after 9 weeks of supplementation (t2).

triathlon is an endurance sport in which athletes compete sequentially in swimming, cycling and running. prolonged and strenuous training combined with insufficient recovery can produce muscular and metabolic stress, resulting in structural and functional damage to the musculoskeletal system leading to a fatigue status, which results in decreased athletic performance. as a consequence of this type of combined exercise, there are also alterations in biochemical markers of exercise-induced muscle damage (eimd) as well as anabolic/catabolic hormones. therefore, their analysis is useful in determining the balance between training loads and recovery. in this sense, it is essential to include different strategies to reduce or prevent eimd, which delay or reduce muscle fatigue and improve sports performance. one of these strategies is the use of different ergogenic aids such as l-citrulline (cit) and nitrates (nit) which have been proposed as both substances produce an increase in nitric oxide (no).

Eligibility criteria:
inclusion criteria: * males between 25 and 35 years old * triathletes * with at least 5 years of experience * without any disease * non smokers * non drinkers of alcohol * not to take any other medications or stimulant substances during the study * 2 weeks without taking other nutritional supplements exclusion criteria: * exclusion criteria: * men under 25 and over 35 years of age. * non triathletes * less than 5 years of experience * with any disease * smokers * alcohol drinkers

Keywords: triathlon performance ergogenic aids muscle fatigue recovery hormones
a study of dental implants coated with bone morphogenetic protein

Conditions: Alveolar Ridge Abnormality

Summary: the purpose of the study is to evaluate implant stability and stimulate clinically relevant horizontal and vertical new bone formation around nobel biocare's bone inductive implant.

common complications encountered when replacing missing teeth with endosseous dental implants include lack of adequate bone volume limiting the possibility of optimal patient treatment. typical limitations include severely resorbed alveolar ridges (height and width) in patients following long-term edentulism. in other cases, the alveolar ridge may have become compromised due to advanced periodontal disease, traumatic extractions, and other trauma disallowing endosseous dental implant placement to meet aesthetic and functional demands. conversely, placing endosseous dental implants to optimally meet aesthetic and functional demands in sites exhibiting alveolar ridge aberrations often results in partial exposure of the endosseous dental implant bone-anchoring surface. in some cases clinicians have attempted to overcome the deficient bone volume by augmenting the anticipated endosseous dental implant site using bone biomaterials, commonly originating from human or animal cadaveric sources, or synthetic biomaterials. the biomaterials have been used alone and in combinations including autologous bone grafts. non-resorbable and bioresorbable barrier devices have been used to prevent dislocation of implanted biomaterials. the ability of the bone inductive implant to form new bone above the level of the resorbed alveolar ridge to immerse the exposed portion of the endosseous dental implant in bone (treatment group 1) and the ability of the bone inductive implant to induce bone formation around stable endosseous dental implants placed into tooth extraction sockets (treatment group 2) without the use of bone grafts, bone biomaterials, or barrier devices will be assessed.

Eligibility criteria:
inclusion criteria: * above the age of 18 years. * 2 teeth or more are missing either upper/lower jaw (treatment gp 1) * 2 or more teeth require extraction either upper/lower jaw.(treatment gp 2) exclusion criteria: * medical risk patients * smoking.

Keywords: bone inductive implant
observational study on multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this is a multicentre observational study which involves 43 of the major italian centres that treat ms. the duration expected for the study participation of each subject was exclusively the necessary one for the screening visit and execution of the ecocolor-doppler test, which could have also been executed on the same day.


Eligibility criteria:
inclusion criteria: * group a (ms) * age 18-55 years; * unisex patients diagnosed with ms according to mcdonald criteria and successive relapse (38, 39), and subjects with cis; * course of the disease: rr-sp-pp-cis; * disease duration (starting from diagnosis): from 1 month to 25 years for subjects with rr, sp, and pp; a maximum of 5 years for subjects with cis; * not in clinical relapse (at least 30 days after the last clinical relapse); * subjects treated or non-treated with immunomodulatory and immunosuppressive drugs; * signature of the informed consent. group b (hc) * age 18-55 years; * absence of significant diseases and lack of familiarity with ms, ie health check-ups (hc); * signature of the informed consent. the subjects included in this group could be, for example, unrelated relatives or spouses of those affected by ms or other diseases in the study or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres. group c (ond) * aged 18-55 years; * subjects with other non-inflammatory neurodegenerative disease (ond), for example parkinson, als, ataxy. group d (ondi) * age 18-55 years; * subjects suffering of other inflammatory neurodegenerative diseases (ondi), for example optical neuromielitys, adem, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases; * signature of the informed consent. exclusion criteria: * • the presence of acute or chronic disease which are disabling or interfere with the design and objective of the study; * clinically proven cardiopathy (nyha ≥ i class); * previous episodes of venal thromboembolism (including either deep venal thrombosis or pulmonary embolism); * neoplasms; * thrombophilia from an anamnestic definition; * diabetes; * primary or secondary pulmonary hypertension and in treatment for it; * concurrent systemic steroid treatments or in the last 30 days; * cerebrovascular diseases current or previous; * episodes of global transitory amnesia; * pregnancy.
melatonin and hyaluronic acid in maxillary sinus augmentation

Conditions: Edentulous; Alveolar Process, Atrophy

Summary: melatonin proved an ability to repair bone defects and enhance osseointegration of dental implants. also, hyaluronic acid has osteopromoting properties. the effect of melatonin and hyaluronic acid on the newly formed bone in maxillary sinus augmentation was evaluated

16 participants with missing maxillary posterior teeth and residual alveolar ridge of at least 5 mm will be equally and randomly divided into two groups. the study group will receive melatonin and hyaluronic acid after sinus membrane elevation and simultaneous implant placement while the control group will not receive any materials after sinus membrane elevation and simultaneous implant placement.

Eligibility criteria:
inclusion criteria: * age range will be between (30 - 50) years old. * patients with missed one or more of posterior teeth with minimum residual bone height 5 mm * adequate inter-occlusal space of at least 8 mm exclusion criteria: * maxillary sinus diseases. * previous sinus surgery like the caldwell-luc operation. * history of chemotherapy or radiotherapy to maxilla. * presence of underwood's septa/severe sinus floor convolutions. * systemic disease affecting bone metabolism. * uncontrolled diabetes mellitus. * heavy smokers. * para functional habits.
synergistic effect of vitamin e & d in reducing risk of effects associated with atypical anti-psychotics

Conditions: Antipsychotics and Neuroleptics Toxicity

Summary: atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tremor), tardive dyskinesia, bradycardia, hypotension, impotence, sleepiness, seizures, severe dreams or nightmares, and hyperprolactinaemia. vitamin d and e, have been the focus of much research in the past fifteen years, which has revealed multiple roles in the development and function of the body. according to mounting data from the domains of epidemiology and neuroscience, vitamin d and e deficiency have been related to a number of neuropsychiatric issues as well as neurodegenerative diseases. additionally, antioxidants like vitamin e help to prevent inflammation and highly reactive oxygen molecules from damaging normal cells. the use of vitamin e and d supplements has been suggested to improve the overall outcomes of psychiatric illnesses and neurological diseases. however, the synergistic effect of vitamins e and d in reducing the risk of the adverse effects associated with atypical antipsychotics and improvement in psychiatric illness is not well understood. therefore, this study was designed to investigate the potential synergistic effect of vitamin e and d supplements for reducing the adverse effects associated with atypical antipsychotics.

inclusion criteria: 1. patients using antipsychotic medications such as quetiapine, olanzapine, or risperidone 3. participants who are between the ages of 20 - 70 years 3. both gender patients male and female 4. patients with no other chronic morbidity

Eligibility criteria:
inclusion criteria: 1. those using antipsychotic medications such as quetiapine, olanzapine, or risperidone. 2. participants who are between the ages of 20 - 70 years are both sex male and female 3. participants who are taking a combination of one or two antipsychotics. 4. participants who were under antipsychotic therapy and not diagnosed with type 2 diabetes mellitus. exclusion criteria: 1. patients at mental hospitals are mostly women who are either pregnant or nursing. 2. patients who were taking anticonvulsants, ketoconazole, or corticosteroids, or who had a history of other mental or neurologic illnesses, as well as those who used phosphor, calcium, vitamin d supplements or teriparatide, were not included in the study. 3. participants were also ruled out if they had preexisting conditions including renal or hepatic failure or a parathyroid disease -
embolization of middle meningeal artery for subdural hematoma in canada (emma can)

Conditions: Subdural Hematoma

Summary: emma-can is a prospective cohort study to assess the safety and effectiveness of mma-embolization for the treatment of csdh. hypothesis- emma reduces the recurrence rate of sdh with or without concomitant surgical evacuation.

the purpose of our study is to conduct a prospective cohort study to assess the safety and effectiveness of mma embolization for the treatment of csdh. all patients with csdh presenting to the emergency room or to neurosurgical outpatient clinic will be screened for potential enrollment. if the subject is willing to participate an informed consent will be obtained. all patients presenting to the emergency room or in neurosurgery clinic with csdh diagnosed on ct scan will be considered for the study. if the patient needs emergent evacuation for clinical reasons, patient will be taken for surgical evacuation before consideration of emma. patients that are more likely to have recurrence after surgical evacuation are those with recurrent csdh, on antiplatelet or antithrombotic treatment. the emma could be used as primary treatment or in conjunction with surgery in these patients or in patients who may not be good surgical candidate. follow up - all patients will be followed after discharge from the hospital at 1, 3 and 6 months interval. the follow up at 1 and 3 months will include plain ct head of the patient, which is standard of care for most patients. the follow up at 6 months will be only clinical follow up. patients will be assessed for recurrence of csdh on ct scan of head. the size of the csdh will be measured and compared to previous scans and peri-procedural morbidity and mortality related to emma will be sought. this will be done at 1 and 3 months post emma.

Eligibility criteria:
inclusion criteria: * all patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic exclusion criteria: * when informed consent is not possible * known allergy to liquid embolic agent

Keywords: embolization middle meningeal artery chronic subdural hematoma
intradiscal gelified ethanol and pulsed radiofrequency versus gelified ethanol injection for discogenic low back pain

Conditions: Low Back Pain

Summary: many different minimally invasive techniques have been used for the treatment of chronic discogenic low back pain refractory to conservative treatments, with various results. the aim of this study is to assess the efficacy of the combination of intradiscal pulsed radiofrequency and gelified ethanol versus gelified ethanol alone, on pain and quality of life of patients sufferring from chronic discogenic low back pain.


Eligibility criteria:
inclusion criteria: * discogenic low back pain \> 6 months, * pain refractory to conservative treatment, * no other aetiology for pain, * pain reported during provocative discography according to standard criteria, * mri imaging indicating disk degenarative disease exclusion criteria: * red flags for low back pain, * lumbosacral radiculopathy, * extruded or sequestered lumbar disc, * severe spinal stenosis, * facet joint syndrome, * sacroiliac joint pain, * neurological disorders, * psychiatric disorders, * rheumatoid arhtritis, ancylosing spondylitis, other autoimmune arthritis, * coagulation disorders, * pregnancy

Keywords: pulsed radiofrequency gelified ethanol